表紙
市場調查報告書

甲氧西林敏銳度黃色葡萄球菌 (MSSA) 感染疾病:開發中產品分析

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 271821
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
甲氧西林敏銳度黃色葡萄球菌 (MSSA) 感染疾病:開發中產品分析 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 59 Pages
簡介

甲氧西林敏感金黃色葡萄球菌 (MSSA) ,是對多數抗生素有抗性的細菌。MSSA通常感染皮膚,不過,也有可能引起肺炎與其他嚴重的感染疾病。症狀有蜂窩性組織炎、伴隨疼痛的皮疹、噁心嘔吐、發熱、肌肉疼痛、腹瀉和腹痛等,發病要素是免疫系統低落,燒燙傷,手術的創傷等。

本報告提供甲氧西林敏銳度黃色葡萄球菌 (MSSA) 感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

甲氧西林敏銳度黃色葡萄球菌 (MSSA) 感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Antibiotx ApS
  • ContraFect Corp
  • Debiopharm International SA
  • Sealife PHARMA GMBH

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12218IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Pipeline Review, H1 2020, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
    • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
    • Basilea Pharmaceutica Ltd
    • BioPlx Microbiomics Pvt Ltd
    • Debiopharm International SA
    • Destiny Pharma Plc
    • Galenus Therapeutics Inc
    • HyPharm GmbH
    • LegoChem Biosciences Inc
    • Naicons Srl
    • Sealife PHARMA GMBH
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
    • afabicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BioPlx-01KS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BioPlx-01WT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceftobiprole medocaril - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exeporfinium chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HY-133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-010699 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAI-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
      • Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
      • Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H1 2020
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020